Organigram Hldgs Inc - OGI STOCK NEWS

Organigram Holdings reported Q1 Fiscal 2025 results with 17% growth in net revenue to $42.7 million year-over-year. The company achieved Adjusted EBITDA of $1.4 million, up from $0.1 million in the prior year period. Key highlights include a $2.3 million increase in international sales, completion of Motif acquisition to become Canada's recreational cannabis market leader, and a strong pro-forma cash position of $113 million with negligible debt.

The company maintains leading market positions in Canada, ranking #1 in vapes, pre-rolls, milled flower, hash, and pure CBD gummies. Adjusted gross margin increased to 33% from 31% year-over-year. The integration of Motif is expected to deliver over $10 million in annual run-rate synergies within 24 months. The company's flagship brands SHRED and BOXHOT reached over $385 million in retail sales over the last 12 months.

Organigram Holdings (NASDAQ: OGI) (TSX: OGI) has announced it will release its first quarter fiscal 2025 financial results on February 11, 2025, before the market opens. The company will host a conference call at 8:00 am Eastern Time on the same day to discuss the results.

Interested participants can register for the conference call through a provided link, with registration recommended at least 10 minutes before the call starts. A webcast option is also available, and a replay will be accessible on Organigram's investor relations website for 90 days following the call.

Organigram Holdings Inc. (NASDAQ: OGI) reported its Q4 and fiscal 2024 results, showing significant growth and operational improvements. The company achieved fiscal 2024 net revenue of $159.8 million, with Q4 net revenue increasing 22% year-over-year to $44.7 million. Q4 adjusted EBITDA reached $5.9 million, up from $0.1 million in the comparative period.

Key highlights include a 17.6% year-over-year growth in recreational shipped sales, 37% adjusted gross margin in Q4, and $8.9 million in Q4 cash flow from operations. The company became Canada's largest cannabis company by market share following the Motif Labs acquisition. Organigram secured significant funding from BAT, including two tranches of a $124.6 million investment, with the final $41.5 million expected in February 2025.

Organigram Holdings (NASDAQ: OGI) (TSX: OGI), a leading licensed cannabis producer, has announced it will release its fourth quarter and fiscal 2024 financial results on December 18, 2024, before market open. The company will host a conference call at 8:00 am Eastern Time on the same day to discuss the results. Interested participants must register in advance to join the call, and a webcast replay will be available within 24 hours after the call's conclusion, remaining accessible for 90 days on the company's investor relations website.

Organigram Holdings has acquired Motif Labs for $90 million upfront ($50M cash, $40M in shares), plus potential $10M in contingent shares. This acquisition makes Organigram Canada's largest cannabis company by market share (12.4%). Key highlights:

- Creates #1 position in vapes (21.7% market share) and strengthens infused pre-roll segment
- Motif generated ~$86M LTM net revenue and $4.7M adjusted EBITDA
- Expected cost synergies exceed $10M over 24 months
- Adds strategic facilities in Aylmer and London, Ontario
- Combines strong brands including Organigram's 'SHRED' and Motif's 'BOXHOT'

Organigram Holdings (NASDAQ: OGI) has launched Edison Sonics gummies, featuring their innovative FAST™ (Fast Acting Soluble Technology) nanoemulsion technology. The product delivers up to ~50% faster onset and nearly double the cannabinoids at peak effect compared to traditional edibles, as verified through pharmacokinetic studies completed in January 2024.

The gummies will be available in two flavors: Kiwi Berry Burst (Sativa) and Red Razz Chiller (Indica), each pack containing two gummies with 5mg THC + 5mg CBD per gummy. The product will be available in major provinces starting early December.

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has closed the second tranche of a C$124,559,674 strategic equity investment by BAT subsidiary BT DE Investments Inc. The investor acquired 4,429,740 common shares and 8,463,435 Class A preferred shares at C$3.2203 per share, for gross proceeds of USD$30,821,684.69. This follows the first tranche closing on January 23, 2024. The investment funds the 'Jupiter' strategic investment pool, which has already made two investments: USD $2 million in Open Book Extracts and €14 million in Sanity Group GmbH. The final tranche is expected around February 28, 2025. Post-closing, the investor owns 30% of common shares and 100% of preferred shares, maintaining the 30% ownership threshold.

Organigram Holdings, a leading cannabis producer, reported a strong Q3 Fiscal 2024, with net revenue of $41.1 million, up 25% YOY. The company achieved an adjusted EBITDA of $3.5 million, a significant improvement from a $2.9 million loss last year. Net income was $2.8 million, compared to a $213.5 million loss in the prior year. The pro-forma cash position stands at $173 million.

Key achievements include a strategic investment in Germany's Sanity Group, the completion of a clinical study on FAST™ nanoemulsion technology, and leading market positions in various cannabis product categories in Canada. The company also signed new international supply agreements in Australia and the U.K.

Financial highlights include a gross margin improvement to 36%, a 22% reduction in SG&A expenses, and a substantial increase in market share across Canadian provinces.

Organigram continues to focus on operational efficiency, product innovation, and international expansion to drive long-term shareholder value.

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has completed a landmark clinical pharmacokinetic study on its FAST™ (Fast Acting Soluble Technology) nanoemulsion technology. The study, conducted through the Product Development Collaboration, revealed promising results:

1. Up to 50% faster onset of cannabis effects compared to traditional ingestibles
2. Improved bioavailability with up to double the cannabinoid delivery at peak
3. Potential for more predictable duration of effects

Organigram plans to leverage this data to substantiate functional technology claims and expects to commercialize FAST™ in fall 2024, starting with gummies. The company views this innovation as a competitive advantage for its ingestible portfolio, addressing key consumer pain points in dosage control and experience predictability.